Tigecycline Dosing in Neonates

Key Bottom Line

Regulatory Status

Off-Label Use in Neonates: Available Evidence

• Standard dose used: ~1 mg/kg IV q12h (analogous to the dose extrapolated from older children)
• Dose escalation: In one neonate, the dose was increased to 2 mg/kg IV q12h after 96 hours due to persistent bacteremia
• Outcome: All 4 neonates had favorable outcomes
• Adverse effect noted: All neonates developed thrombocytopenia after the first week, which resolved after stopping therapy

• Loading doses of 1.8-6.5 mg/kg
• Maintenance doses of 1.25-3.2 mg/kg q12h

Why Dosing in Neonates is Particularly Challenging

1. No PK data exist for neonates or children under 8 years
2. Tigecycline has unique PK properties - large volume of distribution (500-700 L in adults), extensive tissue distribution, and significant interindividual variability
3. Neonatal physiology (immature hepatic/renal function, altered body composition, different protein binding) makes adult/older-child PK extrapolation unreliable
4. Tigecycline in neonates has peculiar PK characteristics (e.g., bacteremia is the predominant neonatal infection, where tigecycline's tissue-heavy distribution is a disadvantage)

Concerns Specific to Neonates/Young Children

• Tooth discoloration: Like tetracyclines, tigecycline may cause permanent yellow staining of developing teeth. In one pediatric series (<8 years), this occurred in 2 of 12 children (17%) receiving prolonged therapy (>19 days)
• Thrombocytopenia: Consistently reported in neonatal case reports after approximately 1 week of therapy
• Monitoring of LFTs, CBC, coagulation, amylase, and lipase is recommended during therapy

Indications for Off-Label Neonatal Use

• MDR/XDR Gram-negative sepsis (e.g., carbapenem-resistant K. pneumoniae, Acinetobacter)
• Confirmed or strongly suspected susceptibility on culture
• Failure or contraindication to all other viable agents
• With infectious disease specialist consultation

Summary

• Kontou A et al., Antibiotics 2023 (PMID: 37370391) - the best available review of newer antibiotics in neonates
• Red Book 2021, AAP Committee on Infectious Diseases, p. 540-541
• Pfizer Tygacil EMA SmPC (Oct 2025)

Apnoea of Prematurity (AOP): Recent Trials and Evidence

Background

1. Caffeine - Core Pharmacotherapy

1a. Methylxanthines (Cochrane Review 2023)

• 18 RCTs, 2705 infants evaluated methylxanthines (aminophylline, caffeine, theophylline) for AOP prevention, treatment, and facilitation of extubation
• Based predominantly on the landmark CAP trial (n=2006):
  • Caffeine probably reduced the composite of death or major neurodevelopmental disability (NDD) at 18-24 months: RR 0.87 (95% CI 0.78-0.97); NNTB 16 - moderate certainty
  • Caffeine probably reduces BPD (RR 0.63, consistent with prior data)
  • Benefit on NDD was strongest in the extubation-facilitation group (RR 0.85)
• Key finding: Caffeine remains the methylxanthine of choice; theophylline and aminophylline are inferior alternatives with more adverse effects

1b. Prophylactic Caffeine in Very Low Birth Weight Infants (Meta-Analysis 2023)

• 11 RCTs, 4375 VLBW infants
• Prophylactic caffeine (before clinical AOP occurs) significantly reduced:
  • AOP incidence: OR 0.31 (95% CI 0.19-0.49, p<0.001)
  • BPD: OR 0.62 (95% CI 0.54-0.71, p<0.001)
  • PDA: OR 0.49 (95% CI 0.30-0.80, p=0.005)
  • ROP: OR 0.76 (95% CI 0.65-0.90, p=0.001)
  • Mechanical ventilation duration and oxygen therapy
• No increased risk of NEC, IVH, or death
• Supports prophylactic rather than reactive initiation

1c. Caffeine: Dose and Long-Term Neurodevelopment (Systematic Review 2024)

• 15 studies, 3530 preterm infants, outcomes tracked from birth to adolescence
• Caffeine reduced AOP: RR 0.59 (95% CI 0.46-0.75) - very low certainty due to heterogeneity
• Caffeine reduced BPD: RR 0.77 (95% CI 0.69-0.86) - moderate certainty
• Higher doses more effective for both AOP control and BPD reduction
• No significant effect on neurocognitive impairment in early childhood
• Possible benefit on motor function in middle childhood (6-11 years): RR 0.72 (95% CI 0.57-0.91) - moderate certainty
• Optimal dose remains unknown; long-term studies still needed

1d. Early vs Late Caffeine Administration (Systematic Review + Meta-Analysis 2024)

• 11 studies, 122,579 patients; early = initiation within 0-2 days of life
• Early caffeine significantly reduced:
  • BPD: OR 0.70 (95% CI 0.60-0.81)
  • IVH: OR 0.86 (95% CI 0.82-0.90)
  • ROP: OR 0.80 (95% CI 0.74-0.86)
  • Late-onset sepsis: OR 0.84 (95% CI 0.79-0.89)
  • PDA: OR 0.60 (95% CI 0.47-0.78)
  • Composite BPD or death: OR 0.76 (95% CI 0.66-0.88)
• However, early caffeine was associated with higher mortality (OR 1.20, 95% CI 1.12-1.29) - likely survival bias in observational studies
• Conclusion: Early caffeine initiation is favoured, but requires additional RCT confirmation

1e. WHEN to Stop Caffeine - Cessation Strategies (Cochrane 2024)

• 3 RCTs, 392 infants; examined early vs late discontinuation and PMA-based vs symptom-based cessation
• Early cessation (<35 weeks PMA) may increase intermittent hypoxaemia episodes in the 7 days after stopping: MD +4.80 episodes (95% CI 2.21-7.39) - low certainty
• Stopping based on resolution of symptoms vs predetermined PMA: very uncertain evidence, all low/very-low certainty
• Practical message: Extending caffeine beyond symptom resolution to ~34-35 weeks PMA may reduce rebound hypoxaemia

2. Landmark RCT: Extended Caffeine for Moderately Preterm Infants (MoCHA Trial, JAMA 2025)

• Design: Multicenter RCT, 29 US hospitals; n=827 infants born 29-33 weeks' gestation; enrolled at 33-35 weeks' PMA
• Intervention: Oral caffeine citrate 10 mg/kg/day vs placebo until 28 days post-discharge
• Primary outcome: Days to hospital discharge after randomisation
• Key results:
  • Length of stay did NOT differ: 18.0 vs 16.5 days (adjusted median difference 0 days; 95% CI -1.7 to +1.7) - FUTILITY threshold reached
  • Days to physiological maturity: no difference (14.0 vs 15.0 days)
  • Infants on caffeine became apnoea-free sooner (6.0 vs 10.0 days, adjusted difference -2.7 days; 95% CI -3.4 to -2.0) - but this did not translate to earlier discharge
  • No difference in readmissions, sick visits, or adverse events
• Conclusion: Extending caffeine beyond hospital readiness criteria does not shorten hospitalisation - challenging the common practice of prolonged post-discharge caffeine therapy in moderately preterm infants

3. Doxapram - Second-Line Respiratory Stimulant

3a. Cochrane Review on Doxapram (2023)

• 8 RCTs, 248 infants (all IV doxapram studies)
• Used for methylxanthine-refractory AOP or to facilitate extubation
• Doxapram vs no treatment: may slightly reduce failed apnoea reduction (RR 0.45; 95% CI 0.20-1.05) - low certainty
• Doxapram vs alternative treatment: very uncertain evidence (very low certainty throughout)
• No long-term safety data from RCTs
• Conclusion: Evidence base is very weak; doxapram use should remain limited to refractory cases pending better trials

3b. Oral Doxapram Phase II RCT (2026 - NEW)

• First RCT of oral doxapram dosing in very preterm infants (<32 weeks on CPAP ≥8 cmH2O)
• Higher dose (48 mg/kg loading, 24 mg/kg/6h): 88% had supra-therapeutic concentrations
• Lower dose (24 mg/kg loading, 12 mg/kg/6h): achieved therapeutic range (1.5-4.0 mg/L) in 47% of infants
• By day 5: oral doxapram improved mean SpO2, reduced FiO2, pCO2, and time SpO2 <90%
• Conclusion: Oral doxapram is feasible; lower dose (12 mg/kg/6h) is sufficient for most infants - paves the way for a Phase III trial

3c. Doxapram and Neurodevelopmental Outcomes at Age 5-6 Years (2024)

• EPIPAGE-2 French national cohort, 2950 children born <32 weeks; 275 (8.6%) received doxapram
• After propensity score matching (821 children, 2:1): doxapram was NOT associated with overall neurodevelopmental disability at age 5-6 years: OR 1.09 (95% CI 0.76-1.57, p=0.63)
• Reassuring signal - doxapram does not appear to harm neurodevelopment

4. Respiratory Support Modalities

HFNC vs CPAP (Meta-Analysis 2026)

• HFNC showed no significant difference vs CPAP in preventing BPD or air leak in preterm infants
• HFNC significantly reduced nasal injury: RR 0.40 (95% CI 0.33-0.49, p<0.00001)
• Evidence certainty: low for BPD and air leak, high for nasal injury
• Clinical take: HFNC is a reasonable alternative to CPAP, particularly when nasal trauma is a concern

Summary Table

Key Clinical Takeaways from New Evidence

1. Start caffeine early (within 48h of life) in all preterm infants <34 weeks - reduces multiple morbidities beyond AOP alone
2. Higher doses (loading 20 mg/kg, maintenance 10 mg/kg/day caffeine citrate) appear more effective than standard doses but optimal dose is still not fully defined
3. MoCHA Trial (JAMA 2025): Extending caffeine post-discharge in moderately preterm infants (29-33 weeks) does NOT reduce hospital stay - an important practice-changing finding
4. Caffeine discontinuation is best guided by symptom resolution; early stopping increases rebound hypoxaemia episodes
5. Doxapram remains a second-line option for methylxanthine-refractory AOP; oral doxapram is emerging as a feasible route; long-term safety appears acceptable
6. HFNC is an acceptable alternative to CPAP for respiratory support with the advantage of less nasal trauma